➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Baxter
Medtronic
Express Scripts
Moodys

Last Updated: January 18, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Dimethyltryptamine

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Dimethyltryptamine?

Dimethyltryptamine is an investigational drug.

There have been 13 clinical trials for Dimethyltryptamine. The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2018.

The most common disease conditions in clinical trials are Depression, Depressive Disorder, Major, and Depressive Disorder. The leading clinical trial sponsors are Heffter Research Institute, Johns Hopkins University, and GH Research Limited.

There are one hundred and forty-two US patents protecting this investigational drug and eight hundred and fifty-eight international patents.

Recent Clinical Trials for Dimethyltryptamine
TitleSponsorPhase
SPL026 (DMT Fumarate) in Healthy Subjects and MDD PatientsSmall Pharma LtdPhase 1/Phase 2
Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use DisorderJohns Hopkins UniversityPhase 2
Effects of Dimethyltryptamine in Healthy SubjectsMatthias LiechtiPhase 1

See all Dimethyltryptamine clinical trials

Clinical Trial Summary for Dimethyltryptamine

Top disease conditions for Dimethyltryptamine
Top clinical trial sponsors for Dimethyltryptamine

See all Dimethyltryptamine clinical trials

US Patents for Dimethyltryptamine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Dimethyltryptamine   Start Trial Methods of improving behavioral therapies Emory University (Atlanta, GA)   Start Trial
Dimethyltryptamine   Start Trial Complex and structurally diverse compounds The Board of Trustees of the University of Illinois (Urbana, IL)   Start Trial
Dimethyltryptamine   Start Trial Factor XIa inhibitors Merck Sharp & Dohme Corp. (Rahway, NJ)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Dimethyltryptamine

Drugname Country Document Number Estimated Expiration Related US Patent
Dimethyltryptamine World Intellectual Property Organization (WIPO) WO2013142873 2032-03-23   Start Trial
Dimethyltryptamine European Patent Office EP3134408 2034-04-22   Start Trial
Dimethyltryptamine World Intellectual Property Organization (WIPO) WO2015164308 2034-04-22   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Baxter
Medtronic
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.